Cover Image

Thioredoxin Reductase Activity and Its Tissue Distribution in the Pathologic Specimens of Patients with Laryngeal Squamous Cell Carcinoma

Hadi Zare Marzouni, Matineh Barati Bagherabad, Simin Sharaf, Mohammad Zarrinkamar, Shahabeddin Shaban, Hoda Aryan, Ehsan Saburi

Background: Squamous Cell Carcinoma (SCC) is the second most common malignancy of the respiratory tract. Recently, researchers believe that thioredoxin system is effective in the cancerization of some tissues. Thus, this study has been conducted with the aim of measuring of thioredoxin reductase (TrxR) enzyme activity and tissue distribution in the pathologic specimens of patients with laryngeal SCC.Materials and Methods: This study was performed on 40 pathologic blocks (20 healthy and 20 tumoral) from 20 patients with laryngeal SCC who were candidates for laryngectomy surgery. The TrxR enzyme activity was measured by the commercial kit. Also, the tissue distribution of TrxR was determined by immunohistochemical staining and the percentage of staining cells (SC%) and staining intensity were calculated. Data were analyzed by using SPSS13 and significant level was set at P≤0.05.Results: The average the TrxR enzyme activity in the healthy and tumoral tissues was 0.004±0.003µM/min/ml and 0.006±0.003µM/min/ml, respectively (ranged 0.0009 to 0.0104 vs. 0.001 to 0.011 ). However, there was no relationship between the TrxR enzyme activity in the tumoral and healthy tissues (P=0.084). The total score of IHC staining in the healthy tissue was 4.45±1.09 whereas the total of these scores in the tumoral tissue 6.25±0.63. The both scores of SC% and staining intensity in the tumoral tissue was significantly higher than the healthy tissue (P<0.001).Conclusion: Based on the results, although the TrxR enzyme activity has not the significant differences in tumoral tissue compare to healthy tissue, but the tissue distribution in tumoral tissue was higher than healthy tissue.[GMJ.2016;5(3):153-159]

Laryngeal; Squamous Cell Carcinoma; Thioredoxin Reductase Enzyme

Schorn VJ, Miles BA. Laryngeal squamous cell carcinoma. ENT Board Prep: Springer; 2014. p. 227-33.

Tong D, editor Managing SCC of the cervical oesophagus. Asia-Pacific Gastroesophageal Cancer Congress, APGCC 2015; 2015.

Armstrong WB VD, Maisel RH. Malignant tumors of the larynx. In: Flint PW, Haughey BH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, et al, editors. Cummings otolaryngology head and neck surgery. ed t, editor: Philadelphia: Mosby elsevier; 2010. 1482-511 p.

Spencer RJ, Rice LW. Squamous Cell Carcinoma. Uncommon Gynecologic Cancers. 2014:81.

Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochemical and biophysical research communications. 2010;396(1):120-4.

Sengupta R, Holmgren A. Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation. Antioxidants & redox signaling. 2013;18(3):259-69.

Sun K, Eriksson SE, Tan Y, Zhang L, Arnér ES, Zhang J. Serum thioredoxin reductase levels increase in response to chemically induced acute liver injury. Biochimica et Biophysica Acta (BBA)-General Subjects. 2014;1840(7):2105-11.

Arner ES, Holmgren A, editors. The thioredoxin system in cancer. Seminars in cancer biology; 2006: Elsevier.

Jan Y-H, Heck DE, Casillas RP, Laskin DL, Laskin JD. Thioredoxin cross-linking by nitrogen mustard in lung epithelial cells: formation of multimeric thioredoxin/thioredoxin reductase complexes and inhibition of disulfide reduction. Chemical research in toxicology. 2015;28(11):2091-103.

Heaton CM, Durr ML, Tetsu O, Zante A, Wang SJ. TP53 and CDKN2a mutations in never‐smoker oral tongue squamous cell carcinoma. The Laryngoscope. 2014;124(7):E267-E73.

Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. Journal of Thoracic Oncology. 2016.

Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus–related oropharyngeal carcinomas. Journal of Clinical Oncology. 2015;33(8):836-45.

Marzouni HZ, Lavasani Z, Shalilian M, Najibpour R, Fakhr MS, Nazarzadeh R, et al. Women's Awareness and Attitude Toward Breast Self-Examination in Dezful City, Iran, 2013. Iranian Red Crescent Medical Journal. 2015;17(1).

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians. 2012;62(4):220-41.

Taylor SM, Kerr P, Fung K, Aneeshkumar MK, Wilke D, Jiang Y, et al. Treatment of T1b glottic SCC: laser vs. radiation-a Canadian multicenter study. Journal of Otolaryngology-Head & Neck Surgery. 2013;42(1):1.

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians. 2014;64(4):252-71.

Berggren M GA, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxine and thioredoxin reductase gene expression in human tumors and cell lines, and the effect of serum stimulation and hypoxia. Anticancer Res. 1996;16:3459-66.

Raffel J BA, Gallegos A, Cui H, Einspahr JG, Alberts DS, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. Jul. J Lab Clin Med. 2003 142(1):46-51.

Kakolyris S GA, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001 7(10):3087-91.

Yokomizo A OM, Nanri H, Makino Y, Ohga T, Wada M, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995 55(19):4293-6.

Wang J KM, Sakurada K, Imamura M, Muriuchi T, Hosokawa M. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin. Blood 1997 89(7):2480-7.

Kawahara N TT, Yokomizo A, Nanri H, Ono M, Wada M, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 1996;56(23):5330-3.

Kim SJ MY, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res. 2005 11(23):8425-30.

Versari S, Longinotti G, Barenghi L, Maier JAM, Bradamante S. The challenging environment on board the International Space Station affects endothelial cell function by triggering oxidative stress through thioredoxin interacting protein overexpression: the ESA-SPHINX experiment. The FASEB Journal. 2013;27(11):4466-75.

Filios SR, Xu G, Chen J, Hong K, Jing G, Shalev A. MicroRNA-200 is induced by thioredoxin-interacting protein and regulates Zeb1 protein signaling and beta cell apoptosis. Journal of Biological Chemistry. 2014;289(52):36275-83.


  • There are currently no refbacks.